Skip to main content

Advertisement

Log in

177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in India

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The choice of an appropriate treatment option in patients with inoperable or metastatic neuroendocrine tumours (NETs) is limited, and approximately 50 % of patients have advanced NET at diagnosis, and 65 % die within 5 years. Treatment with 177Lu-DOTATATE (177Lu-[DOTA0,Tyr3] octreotate) is a promising new option in the treatment of metastatic NETs.

Methods

Patients with metastatic NET who underwent 177Lu-DOTATATE during the period 2009 to 2013 were included in this retrospective study. Follow-up imaging studies including a 68Ga-DOTANOC PET/CT scan and a posttherapy 177Lu-DOTATATE scan were compared with baseline imaging to determine response to treatment. Progression-free survival (PFS) was calculated using the Kaplan-Meier method and Cox regression analysis was also done.

Results

Ten patients (25 %) had a minimal response, 13 (32.5 %) had a partial response and 9 (22.5 %) had stable disease. Progressive disease was seen in 8 patients (20 %), including 6 patients who died during or after the treatment period. The estimated mean PFS in those who received one or two cycles of 177Lu-DOTATATE was 8.3 months (95 % CI 6.2 to 10.3 months) compared to an estimated mean PFS of 45.6 months (95 % CI 40.9 to 50.2 months) in those who received more than two cycles of 177Lu-DOTATATE (log-rank Mantel-Cox Χ 2 = 8.01, p = 0.005).

Conclusion

Our study showed that treatment with 177Lu-DOTATATE should be considered in the management of NETs, considering the limited success of alternative treatment modalities. Treatment response and PFS is determined primarily by the dose delivered and best results are obtained when more than two cycles of 177Lu-DOTATATE are given, with careful monitoring for possible side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  2. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:3–7.

    Article  PubMed  Google Scholar 

  3. De Herder WW, Hofland LJ, Van der Lely AJ, Lamberts SWJ. Somatostatin receptors in gastro-entero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):451–8.

    Article  PubMed  Google Scholar 

  4. De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res. 2009;42(7):873–80.

    Article  PubMed  Google Scholar 

  5. Sward C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, et al. Comparison of [177Lu-DOTA0, Tyr3]-octreotate and [177Lu-DOTA0, Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm. 2008;23(1):114–20.

    Article  PubMed  Google Scholar 

  6. Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406–16.

    Article  CAS  PubMed  Google Scholar 

  7. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140(6):968–76.

    Article  PubMed  Google Scholar 

  8. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.

    Article  CAS  PubMed  Google Scholar 

  9. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–25.

    Article  CAS  PubMed  Google Scholar 

  10. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)] octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33(11):1346–51.

    Article  CAS  PubMed  Google Scholar 

  11. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I–II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.

    Article  CAS  PubMed  Google Scholar 

  13. Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116 Suppl 4:1084–92.

    Article  CAS  PubMed  Google Scholar 

  14. Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Krause BJ, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. In: Baum RP, Rösch F, editors. Theranostics, gallium-68, and other radionuclides. Berlin: Springer; 2013. p. 457–65.

    Chapter  Google Scholar 

  15. Kunikowska J, Królicki L, Sowa-Staszczak A, Hubalewska-Dydejczyk A, Pawlak D, Mikolajczak R, et al. Polish experience in peptide receptor radionuclide therapy. In: Baum RP, Rösch F, editors. Theranostics, gallium-68, and other radionuclides. Berlin: Springer; 2013. p. 467–78.

    Chapter  Google Scholar 

  16. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3] octreotate. J Clin Oncol. 2004;22(13):2724–9.

    Article  CAS  PubMed  Google Scholar 

  17. de Jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43:617–20.

    PubMed  Google Scholar 

  18. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. (86YDOTA0)-DPhe1-Tyr3-octreotide (SMT487) – a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510–8.

    Article  CAS  PubMed  Google Scholar 

  19. Irina R, Robert R, Walter K, Rosemany D, Wendy G. Hepatic artery embolization with combined 131-I-lipiodol and doxorubicin/cisplatin as local radiosensitizers for the treatment of neuroendocrine tumour (NET) liver metastases. J Nucl Med. 2006;47 Suppl 1:105P.

    Google Scholar 

  20. Natasha S, Krishna BA, Madhusudhan V, Meera V, Sharmila B, Tapas D, et al. Lutetium DOTATATE whole body scans: a novel approach for evaluation of neuroendocrine tumours. Indian J Nucl Med. 2011;26(3):135–8.

    Article  Google Scholar 

  21. Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38(9):1669–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51(3):383–90.

    Article  PubMed  Google Scholar 

  23. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    Article  CAS  PubMed  Google Scholar 

  24. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9:261–7.

    Article  PubMed  Google Scholar 

  25. Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg. 1992;163:479–83.

    Article  CAS  PubMed  Google Scholar 

  26. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer. 2005;104(8):1590–602.

    Article  PubMed  Google Scholar 

  27. Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54(1):84–91.

    CAS  PubMed  Google Scholar 

  28. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge the support of the HCG Research Foundation, Bangalore.

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Madhav Danthala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Danthala, M., Kallur, K.G., Prashant, G.R. et al. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in India. Eur J Nucl Med Mol Imaging 41, 1319–1326 (2014). https://doi.org/10.1007/s00259-014-2710-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2710-1

Keywords

Navigation